Compare RBBN & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | GERN |
|---|---|---|
| Founded | 1997 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.1M | 753.3M |
| IPO Year | 2000 | 1996 |
| Metric | RBBN | GERN |
|---|---|---|
| Price | $2.89 | $1.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $6.00 | $3.00 |
| AVG Volume (30 Days) | 700.0K | ★ 7.1M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $868,592,000.00 | $183,403,000.00 |
| Revenue This Year | $5.02 | $147.34 |
| Revenue Next Year | $5.74 | $39.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.38 | ★ 522.13 |
| 52 Week Low | $2.72 | $1.04 |
| 52 Week High | $5.38 | $3.99 |
| Indicator | RBBN | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 43.66 | 55.61 |
| Support Level | $2.86 | $1.30 |
| Resistance Level | $3.00 | $1.45 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 48.44 | 53.70 |
Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.